Shopping Cart 0
Cart Subtotal
AED 0

Ardelyx Inc (ARDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

Summary

Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients, among others. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US.

Ardelyx Inc (ARDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ardelyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Ardelyx Inc, Pharmaceuticals & Healthcare, Deal Details 10

Licensing Agreements 10

Knight Therapeutics Enters into Licensing Agreement with Ardelyx 10

Ardelyx Enters into Licensing Agreement with Shanghai Fosun Pharma 11

Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 12

Equity Offering 13

Ardelyx Prices Public Offering of Shares for USD50 Million 13

Ardelyx Raises USD110 Million in Private Placement of Shares 15

Ardelyx Raises USD86.3 Million in Public Offering of Shares 17

Ardelyx Raises USD30 Million in Private Placement of Shares upon Exercise of Warrants 19

Ardelyx Raises Up to USD78 Million in Private Placement of Shares and Warrants 20

Ardelyx Raises USD69 Million in IPO 22

Ardelyx Inc-Key Competitors 24

Ardelyx Inc-Key Employees 25

Ardelyx Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 07, 2018: Ardelyx announces second quarter 2018 financial results 27

May 08, 2018: Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights 28

Mar 14, 2018: Ardelyx Reports 2017 Financial Results 29

Nov 07, 2017: Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress 31

Aug 09, 2017: Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results 32

May 05, 2017: Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress 34

Feb 17, 2017: Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results 36

Product News 37

04/18/2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings 37

Clinical Trials 38

Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C 38

Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor 39

Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling 40

Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 41

May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C 43

Apr 18, 2017: Ardelyx To Present Poster on TGR5 agonist RDX8940 at Upcoming Spring Medical Meetings 45

Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease 46

Jan 03, 2017: Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Ardelyx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ardelyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ardelyx Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Knight Therapeutics Enters into Licensing Agreement with Ardelyx 10

Ardelyx Enters into Licensing Agreement with Shanghai Fosun Pharma 11

Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 12

Ardelyx Prices Public Offering of Shares for USD50 Million 13

Ardelyx Raises USD110 Million in Private Placement of Shares 15

Ardelyx Raises USD86.3 Million in Public Offering of Shares 17

Ardelyx Raises USD30 Million in Private Placement of Shares upon Exercise of Warrants 19

Ardelyx Raises Up to USD78 Million in Private Placement of Shares and Warrants 20

Ardelyx Raises USD69 Million in IPO 22

Ardelyx Inc, Key Competitors 24

Ardelyx Inc, Key Employees 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ardelyx Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients, among others. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US.

Ardelyx Inc (ARDX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ardelyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Ardelyx Inc, Pharmaceuticals & Healthcare, Deal Details 10

Licensing Agreements 10

Knight Therapeutics Enters into Licensing Agreement with Ardelyx 10

Ardelyx Enters into Licensing Agreement with Shanghai Fosun Pharma 11

Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 12

Equity Offering 13

Ardelyx Prices Public Offering of Shares for USD50 Million 13

Ardelyx Raises USD110 Million in Private Placement of Shares 15

Ardelyx Raises USD86.3 Million in Public Offering of Shares 17

Ardelyx Raises USD30 Million in Private Placement of Shares upon Exercise of Warrants 19

Ardelyx Raises Up to USD78 Million in Private Placement of Shares and Warrants 20

Ardelyx Raises USD69 Million in IPO 22

Ardelyx Inc-Key Competitors 24

Ardelyx Inc-Key Employees 25

Ardelyx Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 07, 2018: Ardelyx announces second quarter 2018 financial results 27

May 08, 2018: Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights 28

Mar 14, 2018: Ardelyx Reports 2017 Financial Results 29

Nov 07, 2017: Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress 31

Aug 09, 2017: Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results 32

May 05, 2017: Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress 34

Feb 17, 2017: Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results 36

Product News 37

04/18/2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings 37

Clinical Trials 38

Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C 38

Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor 39

Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling 40

Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 41

May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C 43

Apr 18, 2017: Ardelyx To Present Poster on TGR5 agonist RDX8940 at Upcoming Spring Medical Meetings 45

Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease 46

Jan 03, 2017: Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Ardelyx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ardelyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ardelyx Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Ardelyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Knight Therapeutics Enters into Licensing Agreement with Ardelyx 10

Ardelyx Enters into Licensing Agreement with Shanghai Fosun Pharma 11

Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 12

Ardelyx Prices Public Offering of Shares for USD50 Million 13

Ardelyx Raises USD110 Million in Private Placement of Shares 15

Ardelyx Raises USD86.3 Million in Public Offering of Shares 17

Ardelyx Raises USD30 Million in Private Placement of Shares upon Exercise of Warrants 19

Ardelyx Raises Up to USD78 Million in Private Placement of Shares and Warrants 20

Ardelyx Raises USD69 Million in IPO 22

Ardelyx Inc, Key Competitors 24

Ardelyx Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ardelyx Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.